Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions.

British journal of clinical pharmacology ·Vol. 59 ·No. 1 ·2005-01-00 ·Pages 118-9; author reply 119

Zullino DF, Khazaal Y

Abstract

暂无摘要

MeSH Terms

Anti-Inflammatory Agents, Non-Steroidal/adverse effects Antidepressive Agents, Tricyclic/adverse effects Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors Cytochrome P-450 CYP2C9 Drug Combinations Gastrointestinal Diseases/chemically induced Humans Serotonin Uptake Inhibitors/adverse effects

Chemicals

Anti-Inflammatory Agents, Non-Steroidal Antidepressive Agents, Tricyclic Drug Combinations Serotonin Uptake Inhibitors CYP2C9 protein, human Cytochrome P-450 CYP2C9 Aryl Hydrocarbon Hydroxylases

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Zullino Daniele Fabio

Khazaal Yasser

References (6)

6 references, click to expand

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
Curr Drug Metab. 2002 Feb;3(1):13-37 PMID: 11876575
Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects.
Br J Clin Pharmacol. 2003 Jun;55(6):591-5 PMID: 12814454
Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
Pharmacogenetics. 2003 Aug;13(8):473-80 PMID: 12893985
A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs.
Drugs Exp Clin Res. 1993;19(5):189-95 PMID: 8174491
Unstable anticoagulation in the course of amitriptyline treatment.
Pharmacopsychiatry. 1996 Jan;29(1):33-7 PMID: 8852533
Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
Eur J Clin Pharmacol. 1999 Feb;54(12):947-51 PMID: 10192756

Article Info

Journal

British journal of clinical pharmacology

Abbr.

Br J Clin Pharmacol

ISSN

0306-5251

DOI

10.1111/j.1365-2125.2005.2212_1.x

Published

2005-01-00

Pages

118-9; author reply 119

Language

English

Region

England

NLM ID

7503323

PMCID

PMC1884968

Subset

Corrections

CommentOn

PMID: 12814454

External Links

PubMed source DOI: 10.1111/j.1365-2125.2005.2212_1.x PMC Full Text View journal details

Analysis Services

Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions.

Contact

WeChat Official Account